Humacyte (HUMA) Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to support Biologics License Application planned for fourth quarter 2023- DURHAM, N.C., July 26,.
DURHAM, N.C., June 05, 2023 Humacyte, Inc. , Humacyte, Inc. , a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale,. | June 5, 2023
26.05.2023 - NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) - Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March .